News Conference News AHA 2016 Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding Shelley Wood November 21, 2016
News Conference News AHA 2016 Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias Shelley Wood November 21, 2016
News Conference News AHA 2016 Subclinical A-fib Common in Older, Asymptomatic Patients Todd Neale November 18, 2016
News Conference News AHA 2016 La FA Subclínica es Común en Pacientes Asintomáticos de Mayor Edad Todd Neale November 18, 2016
News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016
Presentation AHA 2016 PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy Presenter: Michael Gibson November 15, 2016
News Conference News AHA 2016 Stark Mortality Differences Seen in GARY Registry Tracking TAVR and Surgical Replacement Shelley Wood November 14, 2016
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016
News Conference News AHA 2015 Is Watchman Cost-effective? That Depends Where You Look Todd Neale November 07, 2015
News Conference News AHA 2013 RADAR-AF: HF Source Ablation Does Not Benefit Paroxysmal, Persistent A-fib Patients Yael L. Maxwell November 19, 2013
News Conference News AHA 2012 Evidence Continues to Support Dabigatran Treatment in A-fib November 06, 2012